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Acute bronchiolitis is the leading cause of lower respiratory tract infection and hospitalization in children less than 1 year
of age worldwide. It is usually a mild disease, but some children may develop severe symptoms, requiring hospital
admission and ventilatory support in the ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary
dysplasia, congenital heart diseases and immunodeficiency) may be predisposed to a severe form of the disease.
Clinical diagnosis of bronchiolitis is manly based on medical history and physical examination (rhinorrhea, cough, crackles,
wheezing and signs of respiratory distress). Etiological diagnosis, with antigen or genome detection to identify viruses
involved, may have a role in reducing hospital transmission of the infection.
Criteria for hospitalization include low oxygen saturation (<90-92%), moderate-to-severe respiratory distress, dehydration
and presence of apnea. Children with pre-existing risk factors should be carefully assessed.
To date, there is no specific treatment for viral bronchiolitis, and the mainstay of therapy is supportive care. This consists
of nasal suctioning and nebulized 3% hypertonic saline, assisted feeding and hydration, humidified O2 delivery. The
possible role of any pharmacological approach is still debated, and till now there is no evidence to support the use of
bronchodilators, corticosteroids, chest physiotherapy, antibiotics or antivirals. Nebulized adrenaline may be sometimes
useful in the emergency room. Nebulized adrenaline can be useful in the hospital setting for treatment as needed.
Lacking a specific etiological treatment, prophylaxis and prevention, especially in children at high risk of severe infection,
have a fundamental role. Environmental preventive measures minimize viral transmission in hospital, in the outpatient
setting and at home. Pharmacological prophylaxis with palivizumab for RSV bronchiolitis is indicated in specific categories
of children at risk during the epidemic period.
Viral bronchiolitis, especially in the case of severe form, may correlate with an increased incidence of recurrent wheezing
in pre-schooled children and with asthma at school age.
The aim of this document is to provide a multidisciplinary update on the current recommendations for the management
and prevention of bronchiolitis, in order to share useful indications, identify gaps in knowledge and drive future research.
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This intersociety consensus document intends to provide
a multidisciplinary update for the National Health System
(NHS), hospital and emergency department pediatricians,
pediatricians within the national health system, physicians
attending postgraduate schools, nurses and in general
healthcare providers in the pediatric area, concerning the
most up-to-date scientific evidence on treatment and pre-
vention of bronchiolitis, with special focus on high risk
children populations. The drafting of an intersociety
document has for the first time been adopted as a strat-
egy concerning the topic of bronchiolitis, and this docu-
ment results from the cooperation of 20 Italian scientific
pediatric societies. Intersociety documents are currently
considered to be the most effective tool to reach all
pediatric healthcare providers, to convey shared indica-
tions useful in clinical practice, to identify any gaps in
current knowledge and to drive future research.
The workgroup performing the necessary literature re-
search in drafting this recommendation document used
the PubMed database (until October 2013). The work-
group commits to updating the document every 3 years.
Viral bronchiolitis is the most frequent lower respiratory
tract infection in infants [1] and Respiratory Syncytial
Virus (RSV) [2,3] is the most common infecting agent;
however, other respiratory viruses such as Rhinovirus
(RV), Parainfluenza and Metapneumovirus (MPV) have
been recently demonstrated to cause this disease, occa-
sionally in the form of co-infection [4,5]. Bronchiolitis is
the leading cause of hospitalization in infants (with a peak
of hospitalization at the age of 2 months), and a number
of these children will require admission to intensive care
units and mechanical ventilation. Bronchiolitis is associ-
ated with high mortality rates not only in developing
countries, as this disease represents the main cause of
death due to viral infection during the first year of life also
in industrialized countries, with an incidence which is nine
times higher than that of influenza virus infections [6]. Se-
vere forms of the disease requiring hospitalization may be
more frequent in children younger than 3 months of age or
children with pre-existing risk factors such as prematurity,
bronchopulmonary dysplasia, congenital heart diseases and
immunodeficiency [2,7,8]. As regards long-term outcomes,
about 30–40% of children with prior bronchiolitis-related
hospitalizations will experience recurrent bronchospasm
episodes all throughout adolescence and afterwards [9,10].
There is no evidence of efficacy for numerous therapies
commonly used when treating bronchiolitis (bronchodila-
tors, steroids, antibiotics) [11], and supportive treatment
(oxygen and hydration) still remains the recommended ap-
proach, as confirmed by leading international guidelines,
such as the guidelines issued by the American Academy of
Pediatrics [2] (AAP). New evidence has however been col-
lected in recent years concerning new therapeutic options[3,12]. Nonetheless, the small number of treatments effect-
ive for bronchiolitis emphasizes the importance of preven-
tion in decreasing the impact of this disease.
Diagnosis of bronchiolitis
Bronchiolitis is a viral disease the diagnostic workup of
which is divided into two main phases: clinical diagnosis
of bronchiolitis and etiological diagnosis.
Clinical diagnosis of disease and its severity is rooted in
the clinician's interpretation of the constellation of charac-
teristic findings, and is independent from any specific clin-
ical features and diagnostic tests. Children with acute
bronchiolitis in fact may present with a wide range of clin-
ical symptoms, from mild respiratory distress to incipient
respiratory failure [13]. Therefore, a careful physical exam-
ination (rhinorrhea, cough, crackles, wheezing, dyspnea,
polypnea, feeding difficulties, apnea, lethargy) combined
with the collection of clinical history (to assess the course
of the disease and to capture any high risk conditions) are
warranted as the cornerstone of the diagnosis of bronchio-
litis, which in this document makes reference to children
aged up to 12 months. Diagnostic criteria for the disease
include, but are not limited to, the following [13,14]:
 Onset with rhinorrhea and/or upper respiratory
tract infections
 First episode of respiratory distress associated with:
crackles and/or wheezing, use of accessory muscles
or lower chest wall retractions, low O2 saturation
levels, high respiratory rate relative to age, skin color
changes, nasal flaring, fever
 Exposure to persons presenting with upper
respiratory tract viral infections
 Presentation during epidemic season
Elements such as gestational age or birth age and pro-
gression of clinical signs must be carefully assessed.
Despite not being recommended in clinical practice
[2,3], an etiological diagnosis may be useful especially in
the hospital setting to avoid use of antibiotics (once viral
origin has been demonstrated) and to decrease risk of hos-
pital infections by means of “cohorting” (practice by
means of which all children suffering from viral bronchio-
litis are grouped together in order to avoid contact with
susceptible patients).
Tests to identify presence of the virus may moreover
have an epidemiological significance. The virus may be
isolated by the following methods, which aim at identify-
ing either the virus (through genome detection) or its
antigens:
1. Antigen detection (immunofluorescence, enzyme
immunoassay). These are the so-called “Rapid
antigen-detection tests” with an 80–90% sensitivity,
Table 1 Normal respiratory rate and heart rate values
Respiratory rate Heart rate
(normal values) (normal values)
< 2 months: <60/min 0-12 months: < 160/min
2-12 months: <50/min 1-2 years: < 120/min
>1-5 years: < 40/min 2-8 years: < 110/min
6-9 years: < 30/min
10-14 years: < 20/min
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younger than 3 months of age. As the quantity of
antigen required by these tests is rather significant,
their sensitivity is in direct proportion to the
quality of the sample collected. The sample may be
collected by nasal lavage or swab (using flocked
swabs). Results are ready after a short interval
(30–60 minutes).
2. Genome detection (In situ hybridization, traditional
or real-time polymerase chain reaction (PCR)). PCR
is the gold standard diagnostic test in consideration
of its 93-100% sensitivity and its 64-100% specificity.
Although both techniques are extremely valid, antigen
assays are usually used in routine practice since PCR as-
says are more expensive and not always available.
Collecting samples: the sample to be analyzed must be
collected within 6–7 days after the onset of the infection;
if this is not the case, positivity will decrease together
with the viral load [15].
Nasal swabs (using flocked swabs) and nasal lavage
(using at least 3 mL of saline solution) followed by
nasopharyngeal aspirate provide the best specimens
in terms of most effective detection of etiological
agents [16,17].
Neither laboratory tests or radiological exams are usu-
ally indicated for the routine workup of infants with
bronchiolitis [2,3].
Pediatric primary health care assistance
It is important to point out that the milder forms of
bronchiolitis may be adequately managed in the out-
patient setting by primary care pediatricians, thus limit-
ing hospital admissions. In the outpatient setting the
child’s general clinical conditions must be assessed, to-
gether with his/her ability to feed, heart rate, respiratory
rate, oxygen saturation (measured by pulse oximetry
with specific sensors for infants), the presence of any
risk factors and family compliance. If hospitalization is
not indicated, the parents must be instructed when to
ask for primary care pediatricians or the Emergency
Room reassess the child; moreover, parents’ compliance
with indications, as well as their evaluation ability and
the absence of any difficulties that might hinder their
return for a possible reassessment must be ascertained.
Support and pharmacological therapies for outpatients
management are illustrated in the chapter “Treatment
of Bronchiolitis”.
Indications to hospitalization
The admission status must be assessed on a case-by-
case basis, as there have been no findings from physical
examination consistently associated with outcomes of
bronchiolitis [13].Hospitalization is warranted based on the following
conditions:
 O2 saturation persistently lower than 90-92%, entity
of respiratory distress, presence of apnea. In patients
with congenital heart disease or BPD the need for
oxygen therapy must be determined relative to ha-
bitual transcutaneous saturation measured at the
child’s baseline status of well-being and not relative
to the levels in healthy children (e.g. O2Sat might be
88% in a Fallot patient).
 Dehydration
 Moderate–severe bronchiolitis (Table 1 and
Table 2) [18]
Other important factors to take into consideration are:
 Prematurity, gestational age < 37 weeks or birth age
< 6–12 weeks [2]
 Responsivity and alertness
 Decreased hydration and feeding (<50% of usual
fluid intake in preceding 24 h [19])
 Social factors: distance from the hospital, access to
means of transportation or communication, parents’
collaboration and reliability in terms of managing
the child at home or of understanding the clinical
signs associated with the worsening of the disease
 Environmental factors: exposure to cigarette smoke,
humid or cold dwelling, crowded dwelling
 Presence of pre-existing risk factors, which include:
BPD, cyanogenic congenital heart disease and/or
congenital heart disease associated with pulmonary
hypertension, prematurity [2]; other diseases
which might complicate the presentation of acute
respiratory infections include immunodeficiency,
airway malformation, severe neurological deficit
[2,7], cystic fibrosis. In presence of any of these
factors is necessary to consider hospitalizing the
patient and/or possible arranging for the patient to
be closer to a hospital with a pediatric intensive
care unit.
After having be assessed in the Emergency Room, if
hospitalization is not indicated, parents must be instructed
Table 2 Assessment of bronchiolitis severity [18]
Mild Moderate Severe
Respiratory rate Normal to slightly increased Increased Markedly increased compared to
normal values (refer to Table 1)
Respiratory effort Mild chest wall retraction Tracheal tug Marked chest wall retraction
Nasal Flare Nasal flare
Moderate chest wall retraction Grunting
Oxygen saturations No supplemental oxygen requirement,
O2 saturations > 95%
Saturations 90-95% Saturations < 90%, may not be corrected by O2
Feeding Normal to slightly decreased 50-75% of normal feeds < 50% of feeds, unable to feed
Apnoea Nil May have brief episodes May have increasing episodes
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pediatrician or by pediatricians of the local Emergency
Room. Compliance of parents must be ascertained as
well as the absence of any difficulty which might pre-
vent them from returning to the hospital.
Whenever present, admission to the Short-Stay Obser-
vation Ward (Osservazione Breve Intensiva -OBI) is war-
ranted in order to follow clinical progression for patients
for whom hospitalization is not immediately indicated.
Indication to transfer to intensive care unit
Children with severe bronchiolitis must be transferred to
the Pediatric Intensive Care Unit, based on the following
conditions:
 Respiratory failure which requires mechanical
ventilation support (Continuous positive airway
pressure (CPAP) support should be managed as sub
intensive assistance).
 Apnea with desaturation
 Severe impairment of general conditions
Treatment of bronchiolitis (outpatients setting/
emergency room/hospital)
The basic management of bronchiolitis is based on treat-
ments that assure the patient is clinically stable, well oxy-
genated and well hydrated [13], with repeated clinical
assessment. Lacking a specific etiological treatment, ther-
apy for bronchiolitis includes supportive and pharmaco-
logical therapies to control respiratory and systemic
symptoms [2,11,19] (Table 3).
Supportive therapy
Oxygen therapy
In accordance with the AAP guidelines [2], supplemental
oxygen should be administered if O2 saturation levels
are persistently below 90% at ambient air (SIGN [19]
guidelines instead suggest starting O2 therapy in pres-
ence of saturation levels lower than 92%). It is important
that O2 saturation be measured correctly by pulse oxim-
etry (using pediatric probes, with nasal aspiration priorto measurement, avoiding measurement when child is
moving limbs; reading is to be performed when ple-
thysmograph wave intensity is broad and stable, while
measurement is not reliable in case of peripheral vaso-
constriction or of hypothermia of the limbs). Humidified
O2 may be administered by means of nasal prongs or
mask. O2 saturation must be monitored throughout the
entire duration of O2 supplementation and discontinued
when O2 saturation is about 93%, in presence of a stable
improvement of symptomatology, and if the child has re-
sumed intake of fluids and feeds. In subjects with risk fac-
tors for severe respiratory failure (congenital heart diseases,
bronchopulmonary dysplasia, prematurity) monitoring
should continue even after weaning off oxygen therapy
until the patient is completely stabilized, in order to cap-
ture onset of further episodes of hypoxia which might
occur in these children [2].
High flow oxygen therapy with humidified and heated
oxygen (High Flow Nasal Cannula, HFNC) is a new non-
invasive ventilation support modality that generates posi-
tive pressure in the pharynx and decreases workload of
respiratory muscles [20,21]. Preliminary studies suggest
that the use of high flow heated and humidified oxygen up
to 2 L/kg/min (maximum of 10 L/min), may rapidly im-
prove oxygen saturation in infants suffering from bron-
chiolitis [22]. An advantage of this respiratory support
technique moreover lies in the fact that it may be used
also in pediatrics wards, and not only in Pediatric Inten-
sive Care Units [23]. Studies are currently ongoing to as-
sess efficacy of HFNC ventilation support relative to major
outcomes, such as length of hospital stay and need for
transfer to Intensive Care Unit.
Oxygen therapy may be discontinued and discharge
may be taken into consideration for children presenting
with O2 saturation levels ≥ 93-94% [19], who have re-
sumed feeding and who experience minimal respiratory
distress [2].
Nebulized hypertonic saline solution
The use of nebulized hypertonic 3% saline solution dur-
ing bronchiolitis has been well documented in recent
Table 3 Treatment of bronchiolitis
Supportive therapy
Oxygen therapy If O2Sat < 90-92% AAP, 2006 [2] SIGN 2006 [19]
Nebulized 3% hypertonic saline Safe and effective Cochrane (Zhang) 2013 [24]
Recommended Morawetz, 2011 [25]
Ralston, 2011 [26]
Kuzik, 2007 [27]
Mandelberg 2010 [28]
Respiratory physical therapy
during acute phase of disease
Not effective Cochrane (Roquè), 2012 [36]
Environment humidification Insufficient evidence Cochrane (Umoren), 2011 [35]
Pharmacological therapy
Nebulized Beta 2-agonists Not effective (the possibility of a therapeutic
trial of salbutamol is contemplated)
Cochrane (Gadomski), 2010 [37]
Hartling, 2011 [38]
Nebulized adrenaline Decreases hospitalizations in patients presenting to ER Hartling 2011 [38]
Skjerven 2013 [39]
Nebulized and systemic steroids Not effective Cochrane (Fernandes) 2013 [41]
Hartling, 2011 [38]
Blom, 2010 [40]
Corneli, 2007 [42]
Nebulized adrenaline + systemic steroids Further studies are necessary Plint, 2009 [43]
Antibiotics Only in selected cases (bacterial co-infection/
pre-existing diseases)
Cochrane (Spurling) 2011 [44]
Pinto, 2012 [45]
Ribavirin Only in selected cases (severe forms/pre-existing diseases) Cochrane (Ventre) 2010 [46]
Nebulized DNase Not effective Cochrane (Enriquez) 2012 [53]
Montelukast Apparently not effective Zedan, 2010 [47]
Amirav 2008 [48]
Bisgaard 2003 [49], 2008 [50]
Proesmans, 2009 [51]
Kim, 2010 [52]
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clinical scores and length of hospital stay. However fur-
ther large-scale studies are needed before conclusions
can be made.
Nebulized hypertonic saline has been used both in the
mild and in the moderate-severe forms of the disease in
the outpatient settings and in hospital [24]. The mech-
anism of action of nebulized hypertonic saline solution
seems to be linked with a decrease of airway edema, im-
proved ciliary clearance of mucus and decreased respira-
tory secretion viscosity [28]. Aerosol administration of
hypertonic 3% saline solution is effective and well toler-
ated (uncomplicated by onset of bronchospasm) even
when not administered in association with bronchodila-
tors [29]. According to available studies, examined in a
recent Cochrane [24], hypertonic saline has been admin-
istrated every 2 hours in hospitalized patients during the
initial treatment phase (the first 6–8 hours), and every4–6 hours thereafter. At the Emergency Room, instead,
2–3 consecutive doses have been administrated even less
than every 2 hours (30 minutes). The most widely used
saline solution volume in these studies is 4 mL. No sig-
nificant adverse events related to hypertonic saline inhal-
ation, such as tachycardia, hypertension, pallor, tremor,
nausea, vomiting and diarrhea were observed in these
trials. The inhalation therapy was administered via pneu-
matic nebuliser in most of the studies, but further stud-
ies are required to compare different nebulisers [24].
Nasal aspiration
International guidelines currently in use [2,19,30] rec-
ommend superficial aspiration of the upper airways es-
pecially in younger children in order to improve airway
patency and to ease feeding difficulties. Deep airway as-
piration in presence of bronchiolitis is on the other hand
not recommended, as one study demonstrated that this
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hospital stay [31].
Feeding and hydration
In presence of bronchiolitis, maintaining an adequate
hydration may be difficult because of the concomitance
of fever, tachypnea, and difficulties in taking feeds and
liquids [2,19]. Breastfeeding or feeding with baby bottle
should be encouraged for all breastfed infants who are
able to feed, in order to replace fluid losses [14]. Feeding
2–3 hourly with decreased volumes may be helpful to
prevent the risk of inhalation [18]. In case of moderate
or severe bronchiolitis associated with difficulties in oral
intake of liquids, rehydration may be administered intra-
venously or by nasogastric tube [32]. According to a re-
cent study [33] there are no significant differences
between the two modalities of liquid administration in
terms of length of hospital stay, transfer to intensive care
and need for mechanical ventilation, although the place-
ment of the nasogastric tube has been shown to be the
easier maneuver.
Fluid and electrolyte balance must be accurately moni-
tored, especially when administering fluids intravenously
to avoid onset of hyponatremia and/or inappropriate se-
cretion of ADH, complications which may occur during
bronchiolitis [2] and worsen prognosis of this disease [34].
Chest physiotherapy and ambient humidification
While evidence supporting usefulness of ambient humidi-
fication is insufficient [35], it has been demonstrated that
chest physiotherapy (vibration and percussion techniques)
is ineffective during the acute phase of bronchiolitis [36].
Pharmacological therapy
Beta2-agonists
As per international guidelines [2,19], two recent system-
atic reviews [37,38] have confirmed that inhaled beta ago-
nists are not effective for bronchiolitis, in that they do not
improve oxygen saturation, do not decrease need for and
length of hospital stay nor reduce overall duration of
symptoms. However, as a favourable response may be ob-
served in a number of cases, a single therapeutic trial with
salbutamol by aerosol may be considered, in particular in
children with a family history of allergy, asthma and/or
atopy. This therapy should not be continued lacking a
documented clinical improvement (decrease of respiratory
rate and/or respiratory effort) 15–30 minutes after the trial
inhalation treatment [14].
Nebulized adrenaline
A recent meta-analysis reviewed available studies on the
use of nebulized adrenaline for bronchiolitis and con-
cluded that it might be effective in decreasing need for
hospitalization in children presenting to the emergencyroom, whilst it was not noted to be effective in decreas-
ing length of hospital stay in hospitalized children [38].
A recent Norwegian multicenter study confirmed that
administering nebulized adrenaline to hospitalized chil-
dren is not more effective than nebulized 0.9% saline so-
lution in terms of length of hospital stay, clinical score
and need for supportive therapy (O2, ventilation sup-
port) [39]. Because of lack of studies, short duration of
action, and potential adverse effects, home use of nebu-
lized adrenaline is not recommended by international
guidelines [2,19], which suggest that a bronchodilator
(salbutamol) trial would be more appropriate in the of-
fice/clinic setting. Further studies are necessary to evalu-
ate the early use of nebulized adrenaline.
Systemic and nebulized steroids
Large reviews performed over the years concerning the use
of both systemic and inhalation steroids for bronchiolitis
[38,40-42], have shown that these drugs are not effective in
decreasing incidence and duration of hospitalization or in
improving short– and long-term prognosis. This is prob-
ably due to the fact that bronchiolitis is characterized by a
profound neutrophilic airway inflammation. There is no
consistent clinically relevant association of therapy with sys-
temic or inhaled glucocorticoids and improved outcomes
in either outpatient or inpatient settings [41].
Association of adrenaline and steroids
A multicenter randomized study involving children aged
between 6 weeks and 1 year [43] demonstrated that treat-
ment with adrenaline via aerosol and high-dose dexa-
methasone per os administered at the Emergency Room
reduces risks of hospitalization during the first 7 days of
the disease, suggesting a synergism of the two medicinal
products. However, the study had not been designed to as-
sess the effect of the combination therapy and was the sub-
ject of controversy because of the high steroid dose used.
Antibiotics
The AAP guidelines [2] suggest that antibiotics be used only
in cases of bronchiolitis with bacterial co-infection, as docu-
mented by culture or molecular tests, and in children with
severe bronchiolitis admitted to the Intensive Care Unit
[44]. The habitual use of antibiotics in case of bronchiolitis
must be avoided because of the risk of side effects, signifi-
cant costs and possible development of antibiotic resistance.
It has been suggested but not been confirmed that
macrolides may have an anti-inflammatory and immu-
nomodulator effect in presence of bronchiolitis [45] and
therefore they are not to be used for this purpose.
Antivirals
Current guidelines do not recommend use of ribavirin
as therapy for bronchiolitis [2,19,30]. A recent review
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cient to recommend the use of ribavirin in the treatment
of bronchiolitis.
Other therapies
Other pharmacological and supportive treatment such
as montelukast, DNase, inhaled furosemide, methylxan-
thine, have been assessed in the treatment of bronchio-
litis in pediatric subjects.
Currently available studies do not show results concern-
ing efficacy of montelukast in the treatment of bronchiolitis
and prevention of recurrent post-bronchiolitis wheezing
[47-52].
There is no scientific evidence supporting efficacy of
inhaled DNAse in improving clearance of respiratory se-
cretions [53]. The use of methylxanthine (caffeine and
theophylline) has also been proposed to reduce apnea in
presence of bronchiolitis [54,55], however the lack of precise
epidemiological data concerning the incidence of central
sleep apnea does not allow to confirm its usefulness [56].
Table 3 summarizes the evidence relating to therapy
for bronchiolitis.
Criterias for discharge
 Sustained autonomy from any kind of respiratory
support and O2 saturation levels > 92-94% at
ambient air
 Stabilization of clinical presentation
 Adequate oral intake of fluids and feeds (>75%) [19]
 Adequacy of the family unit in terms of providing
monitoring and possible continuation of therapy
at home
 Possibility, if necessary, of obtaining pediatric health
care assistance locally.
Prevention
Prevention of bronchiolitis in pediatric subjects basically
includes environmental prophylaxis to decrease transmis-
sion of respiratory infections and, specifically for RSV
bronchiolitis, pharmacological prophylaxis with adminis-
tration of humanized monoclonal antibodies (palivizumab)
during the epidemic season in particular categories of chil-
dren at risk. There is no vaccine against RSV available.
Environmental prophylaxis
Environmental prophylaxis is indispensable to decrease
diffusion of the virus in the hospital setting, at outpatient
clinics, and at home, since the virus is easily spread by air-
borne transmission, via saliva droplets, and through con-
tact with contaminated objects and surfaces (hands,
garments, toys, medical instruments, kitchen utensils etc.)
on which the virus may deposit and remain active for sev-
eral hours [2,57].Compliance with hygiene measures for hands and
contaminated surfaces has been well established to be
an easy, non-costly and very effective technique in redu-
cing epidemic diffusion of RSV and other respiratory vi-
ruses [58], with RSV hospital infection rates dropping
from 4.2 to 0.6-1.1% in children aged < 2 years and from
34.8% to 2.1-3.3% in children presenting with congenital
heart diseases [59].
Environmental prophylaxis is to be carried out com-
plying with the indications summarized below [2,19,60]:
 frequent handwashing and decontamination of
hands using alcohol solutions, cleaning of solid
surfaces using water and disinfectants (alcohol based
or antibacterial detergents are to be privileged in
case of contamination with abundant organic
material) or sodium hypochlorite. In the hospital or
outpatient clinic setting, multiple-use medical equip-
ment (e.g. stethoscopes) must also be
decontaminated.
 sharing kitchen utensils and personal effects must be
avoided for subjects with known infection.
 subjects presenting with respiratory infection
symptoms are recommended to cover nose and
mouth with masks and to wash hands prior to
touching anything.
 attendance at community settings or environments
where risks of contact with infected persons are
high, is to be reduced to a minimum as far as
possible for young children and in particular those
belonging to the aforesaid risk categories.
 avoid exposure to secondhand cigarette smoke since
this increases risks of developing respiratory
infections [2].
In addition to those described above, several indica-
tions have been proposed with a view to limiting hospital
RSV infections in the wards where high risk subjects are
hospitalized [2,19,61,62]:
 use of rapid tests to identify RSV-positive patients
and to cohort them apart from RSV negative
patients
 use of disposable gloves and white coats for healthcare
providers who are in contact with the patient
 use of barrier devices in case of maneuvers which
put into contact with respiratory secretions (feeding,
airway aspiration, aerosol therapy)
 decrease of the number of persons entering in
contact with high risk patients during the
epidemic period.
 Compliance with these recommendations has led
to a 39–50% decrease of RSV hospital infections
[63,64].
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Palivizumab is a humanized monoclonal antibody that
binds the F protein on the surface of RSV thus blocking
the fusion of the virus membrane with the target cell
membrane. The pharmacokinetic properties of palivizu-
mab have been analyzed in preterm infants with a gesta-
tional age of ≤35 weeks (wGA) and birth age ≤6 months
[65], and in children presenting with BPD aged ≤2 years
[66]. Results have shown that palivizumab is tolerated well
and that IM administration of a 15 mg/kg dose once a
month helps maintain average antibody serum concentra-
tions sufficient to prevent RSV infection. In consideration
of its half-life of approximately 20–30 days, clinical studies
findings and guidelines issued by numerous pediatric sci-
entific societies suggest that monthly administration of
palivizumab is indicated from the start of the epidemic
period for up to 5 doses [67]. Efficacy and safety of palivi-
zumab have been documented also by 2 multicenter ran-
domized studies conducted on preterm infants younger
than 6 months and preterm infants younger than 2 years
and presenting with BPD respectively [68], as well as on
children with hemodynamically significant congenital
heart diseases [69]. These studies have demonstrated effi-
cacy of prophylaxis in decreasing the number of hospitali-
zations and reducing length of hospital stay without any
findings of serious adverse events. Pursuant to these stud-
ies, the FDA has granted authorization to marketing of
the drug for the aforesaid risk categories.
Numerous scientific societies have issued indications
concerning categories of subjects who should receive
treatment, during the epidemic period, relative to gesta-
tional age and birth age [67,70-72]. There is substantial
consensus concerning treatment of subjects presenting
with specific congenital heart diseases (please refer to
the chapter “Children with heart disease”), subjects with
BPD that required therapy during the six months pre-
ceding the epidemic season (through the second birth-
day) and of preterm children with ≤ 32 wGA (until the
first birthday). As regards the category of children with
33 to 35 wGA, indications arising from epidemiological
studies conducted in various countries differ in part re-
garding duration of prophylaxis and presence of identi-
fied risk factors. For subjects of 33 to 35 wGA + 6 days,
prophylaxis is recommended in the epidemic period
during the first 90 days of life (therefore up to 3 doses)
in presence of at least 1 of the 2 risk factors indicated:
attendance of the child in a community setting and/or
presence of one or more cohabitees younger than 5 years.
In Italy, indications issued by the Italian Society of Neo-
natology (SIN) concerning prophylaxis date back to 2004
[72], however there is no unanimous consensus concern-
ing application of said indications in subjects with 33–35
wGA. The SIN Board has recently appointed a multidis-
ciplinary task force to update current recommendationsbased on the new international and national scientific evi-
dence; to this end, the currently ongoing analysis of the
data generated by the Italian multicenter study sponsored
by SIN in collaboration with the Italian National Research
Councils (CNR) will in all likelihood yield useful elements
[73], thus allowing to identify risk factors for RSV bron-
chiolitis hospitalization in infants with ≥ 33 wGA and to
define the birth age cut-off prior to which prophylaxis is
the most useful. The intersociety document will be up-
dated based on indications generated by the study.
Vitamin D
Recent studies have demonstrated that infants with vitamin
D deficiency at birth face a higher risk of developing RSV
infection during the first year of life [74] and that vitamin D
supplementation allows to decrease risks of viral respiratory
tract infections [75]. These data suggest that vitamin D sup-
plementation for pregnant women and for infants might be
a useful strategy in preventing viral respiratory infections
causing bronchiolitis [74,75]. Currently recommended
doses are 400 IU/day for children younger than one year
and 600 IU/day for children older than one year. Further
interventional studies are necessary to assess the true role
played by vitamin D in preventing the disease.Later respiratory outcomes of bronchiolitis
RSV infections in infants may interfere with normal
immunological and pulmonary development and might
correlate with an increased incidence of recurrent
bronchospasm in preschool-aged infants, and with asthma
and decreased respiratory function in school-aged children
[9,10]. Recent studies have demonstrated that also when
caused by other respiratory viruses, such as Rhinovirus,
bronchiolitis associates with a greater risk of recurrent
wheezing [76]. Post-bronchiolitis syndrome is more fre-
quent in severe cases of RSV bronchiolitis which required
hospitalization. Recent Northern European follow-up
studies conducted throughout adult age (18 and 30 years)
have demonstrated that up to 30 – 40% of subjects who
had been previously hospitalized because of bronchiolitis
presents with asthma and uses antiasthmatic drugs [77].
However, it is as yet unclear whether the viral infec-
tion is the direct cause of the subsequent development
of asthma (by damaging the airways) or if it instead acts
by “unmasking” asthma (or bronchial hyperactivity) in
genetically or structurally predisposed children. A recent
randomized, placebo-controlled, double-blind study [78]
has demonstrated that prophylaxis with Palivizumab in
healthy premature children (33–36 wGA) is able to de-
crease by 61% the number of days with bronchospasm
during the first year of life, thereby supporting the hy-
pothesis of a direct damage caused by the virus. No
similar studies are available in children born at full term.
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It is well known that RSV infections may be severe and
even potentially fatal in specific populations of high risk
newborns and infants.
These groups of patients were traditionally identified
mainly based on the “prematurity” factor, building on
the axiom that “the greater the prematurity, the greater
the risk of developing severe RSV disease”. In actuality,
in recent years awareness has been reached to the effect
that significant risks of severe RSV infections may be de-
tected in infants and children suffering from a number
of rare medical conditions for which prematurity might
be only a possible risk cofactor [7]. In such children, risk
is not associated with immaturity of the respiratory tract
but rather with the presence of specific anatomical,
functional, immune and pathophysiological conditions
such as to generate major risks of severe disease in pres-
ence of bronchiolitis [7,79-81].
Children with congenital neuromuscular diseases
might have poor residual functional capacity, ineffective
coughing because of respiratory muscle weakness, de-
creased glottal closing ability, decrease of spontaneous
physiological movements with reduction of normal ven-
tilation redistribution, and high prevalence of gastro-
esophageal reflux with consequent repeated inhalation
and aspiration syndromes [82].
The latter issue is of course present also in patients
presenting with any of a number of malformation syn-
dromes or sequences (e.g. Pierre-Robin, CHARGE, Jeune
syndrome etc.) in which normal interactions between
swallowing, respiration and food bolus transit are af-
fected [7,79-82].
Another category of high risk children is represented
by patients with cystic fibrosis. The RSV infection in
these children has been documented to accelerate the
respiratory function decline which they will be facing
over the years, causing a more rapid onset of wheezing
and bacterial superinfections. The known close correlation
between RSV and Pseudomonas aeruginosa is crucial in
this process: indeed, proliferation and epithelial adhesion
of the latter pathogen is facilitated by the concomitant
presence of RSV [7,83]. The preliminary results of a recent
study suggest a trend towards less RSV-related hospitaliza-
tions in children with cystic fibrosis treated with palivizu-
mab, however the study involved few patients and results
are to be considered as exploratory [84].
Patients with Down syndrome have long been consid-
ered to be at high risk for RSV exclusively because
underlying severe heart disease is often present. In ac-
tuality, according to cohort studies conducted in the
Netherlands and in Israel collecting data starting at birth
have demonstrated that the incidence of RSV-related
hospitalizations is of approximately 10% (about 3–4
times higher than in the normal population) in all Downsubjects, also in children without congenital heart dis-
ease, as associated with their documented state of rela-
tive T lymphocyte immunodeficiency [85]. This finding
suggests that specific prophylactic measures are war-
ranted in these children during their first two years of
life [85-87].
Finally, a mention must be made of the composite group
of newborns and infants who might develop a severe RSV
disease because of their reduced immunological compe-
tence [88-90]. Response of the immune system against
RSV, as is known, involves the innate epithelial response
(at the level of nasal mucosa), secretory antibody response
(specific IgG, at the level of the upper airways limiting pas-
sage of the virus to the lower airways), and, finally, the T
lymphocyte response, which is responsible for viral clear-
ance and resolution of the RSV infection.
Patients with congenital immunological syndromes,
primary or secondary immunodeficiency (such as bone
marrow or solid organ transplant recipients, patients
with SCID, Di George or Wiskott-Aldrich syndromes,
patients with neonatal HIV, etc.) demonstrate a marked
inability to clear the virus, to prevent its replication or
to limit its potential to determine pulmonary damage
[7]. Thus, these patients are destined to be RSV carriers
for a longer period of time, with higher viral loads and
with greater virulence. In this respect, patients at greater
risk are precisely those with immunodeficiency affecting
the T lymphocyte response, while a decrease in effective-
ness of the B-mediated antibody immune response is
not as severe [89,90].
Unfortunately, methodologically valid scientific docu-
mentation supporting safety and efficacy of anti-RSV
prophylaxis with palivizumab in these populations is still
lacking. In consideration of the low incidence of these
conditions, randomized studies are not feasible or are
difficult to propose, and this is a limitation which is not
expected to be overcome in the foreseeable future.
However, experts do recommend that prophylaxis with
palivizumab be considered in children presenting with
neurological or neuromuscular diseases, genetic syn-
dromes receiving oxygen therapy or ventilation at home
during the first and second year of life and during epi-
demic periods.
Children with heart diseases
Approximately 8 children out of 1000 live births suffer
from congenital heart disease (CHD) at birth, and ap-
proximately 50% of these children present also with
hemodynamically significant impairment requiring
medical and/or surgical and/or invasive cardiological
therapeutic measures, often during the very first years
of life. Children with hemodynamically significant con-
genital heart diseases are at higher risk of possibly se-
vere and potentially fatal complications arising from
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hospital-acquired RSV infection [91-94].
In 2004, Cabalka [95] pointed out that young children
suffering from hemodynamically significant CHD asso-
ciated with pulmonary hyperflow, pulmonary conges-
tion and left/right shunt, or with cyanosis, present with
multiple and complex cardiocirculatory and respiratory
pathophysiological risk factors that impede an adequate
compensatory response to any intercurrent disease. These
infections may complicate management of heart failure or
of cyanogenic heart diseases and/or induce or worsen pul-
monary hypertension, ultimately making it necessary to
postpone an already scheduled surgical procedure or jeop-
ardizing the outcome of heart surgery in the post-surgery
phase. The RSV hospital acquired infection is an un-
favourable perioperative prognostic factor in children
presenting with CHD requiring surgery [96]. Moreover,
the virus may cause cardiac complications in hospitalized
children, such as sinoatrial block, tachyarrhythmias,
atrioventricular block of varying entity, pericarditis
and myocarditis [97]. The efficacy and safety of palivi-
zumab in children presenting with hemodynamically
significant congenital heart diseases has been docu-
mented by a large multicenter, randomized, double-
blind prospective study comparing palivizumab and
placebo [69]. This study has confirmed the efficacy of
prophylaxis in decreasing the number of RSV-related
hospital admissions (−45% globally; −58% of children
with non-cyanogenic heart disease; −29% of children
with cyanogenic heart disease), as well as length of
these hospital stays (−56%) without any unfavourable
effect on surgical outcomes. The Italian Society of
Pediatric Cardiology (SICP) [98] also drafted in 2006
indications concerning prophylaxis with palivizumab
in patients suffering from childhood congenital or ac-
quired “severe” heart diseases, in order to better define
the concept of “hemodynamically significant” heart
disease and therefore render the cost–effectiveness ra-
tio of prophylaxis more acceptable.
The following categories of children are to be consid-
ered as suffering from “hemodynamically significant”
congenital heart disease and as eligible for prophylaxis
with Palivizumab:
 children aged ≤ 2 years at the beginning of the RSV
epidemic season presenting with either congenital or
acquired hemodynamically and clinically relevant
heart diseases and cardiomyopathy such as:– Heart diseases with significant pulmonary hyperflow
(cardiomegaly and/or polypnea and/or radiographic
pulmonary congestion and/or failure to thrive and/
or medical therapy and/or recurrent lower
respiratory tract infections)– Cyanogenic heart disease prior to surgical
procedure or after a palliative procedure
– Primary or secondary pulmonary hypertension
(equal to or greater than 50% of systemic pressure)
– Heart diseases associated with pulmonary venous
congestion
– Dilated cardiomyopathy on medical therapy to
treat heart failure
– Heart diseases after surgical or other procedures
until medical therapy for heart failure is
discontinued
– Recipients of heart transplantAdministration modalities and doses are comparable
to those for other categories at risk.
In children undergoing surgery with extracorporeal
circulation and who continue to be at risk for RSV infec-
tion, a post-surgery dose of palivizumab may be admin-
istered as soon as the child is considered to be clinically
stable (because of a 58% decrease in serum levels of pali-
vizumab that was observed after cardiopulmonary by-
pass surgery).
Subjects presenting with the following conditions are
not eligible for prophylaxis with Palivizumab:
 mild or moderate heart diseases which do not
require medical treatment, surgery or other kind of
intervention during the first 24 months of life
(for example small uncomplicated inter-atrial or
intraventricular defects, small patent ductus
arteriosus, mild aortic coarctation, mild–moderate
pulmonary or aortic stenosis, partial atrioventricular
canal defect)
 children presenting with mild cardiomyopathy
which does not require therapy
 children with CHD which was adequately corrected
by surgery, without any hemodynamically significant
sequelae (please refer to eligibility criteria).
Conclusion
Bronchiolitis is the leading cause of hospitalization in chil-
dren younger than one year, and at times requires admis-
sion to the intensive care unit. Children younger than
3 months or children presenting with risk factors such as
prematurity, bronchopulmonary dysplasia, congenital heart
diseases and immunodeficiency and other malformation
syndromes or diseases are at particular risk of severe and
potentially fatal bronchiolitis. Primary prevention is feas-
ible by carefully implementing environmental prophylaxis.
In subjects at greater risk, prophylaxis with Palivizumab
against the most common responsible infecting agent
RSV, is indicated during the epidemic period, as recom-
mended by scientific societies. Assistance provided to chil-
dren with bronchiolitis is optimized by implementing
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bust scientific evidence concerning hospitalization criteria,
diagnosis, monitoring, treatment. This will have a major
favorable effect on these children, their families and on
direct and indirect costs generated by the disease and by
possible later outcomes. This Document will be accord-
ingly and consistently updated as new evidence arises in
this field.
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